ADHD Wiki
English

Omega-3 supplements

Full page: about 4 min Draft — not yet reviewed by a human

Summary

  • Child and adolescent findings conflict; UK NICE guidance advises against fatty acid supplements for ADHD treatment.
  • Better test scores need not mean better daily symptoms. Evidence for supplementing only low levels remains limited.

Ways to apply

  1. On your own

    Free, no special equipment to buy

    1. Record a daily difficulty, e.g. distraction in class; track daily functioning, beyond test scores.
    2. Ask a clinician whether supplements are needed. Do not use them to replace established treatment.
    3. Do not buy tests or supplements solely on claims that people with low levels benefit more.

Fish oil is not yet routine treatment for childhood ADHD

Research-backed

UK NICE guidance advises against fatty acid supplements to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents(NICE, 2018).

Findings differ: a 2023 Cochrane review found no improvement in parent-rated symptoms; a 2026 review found a tiny overall improvement, with substantial variation between studies. The latter mainly pooled omega-3 studies; its authors also considered it difficult to use as a standalone treatment. These child studies cannot directly establish adult benefits(Gillies et al., 2023; Huang & Kam, 2026).

Better test scores need not mean better daily symptoms

Research-backed

The 2026 review found greater improvements on cognitive tests than on ratings of everyday behavioral symptoms. A 2021 review also found no improvement in quality of life(Huang & Kam, 2026; Händel et al., 2021).

Deciding whether supplementation is worth continuing therefore centers on whether the original difficulties in daily life have actually changed. Relying only on a better test score can lead to overestimating its practical benefits.

Low levels are not yet a basis for choosing who should supplement

Research-backed

A 2026 review of child studies found that symptoms might improve more in children whose omega-3 levels were low before supplementation. However, trials measured different blood components and lacked a common threshold for low levels.

The authors therefore treated this as a preliminary clue, insufficient to recommend supplementation based on test results. Current findings also fall well short of supporting commercial claims that a test can identify who needs supplements(Fu et al., 2026).

Evidence

References (5)
  1. GuidelineAttention deficit hyperactivity disorder: diagnosis and managementNICE (2018). NICE guideline NG87
  2. Meta-analysisPolyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescentsGillies Donna, Leach Matthew J, Perez Algorta Guillermo (2023). Cochrane Database of Systematic Reviews
  3. Meta-analysisPolyunsaturated fatty acid (PUFA) supplementation and ADHD outcomes in children and adolescents: a systematic review and meta-analysis of randomized controlled trialsHuang Ruoxuan, Kam Yiu-Wing (2026). European Child & Adolescent Psychiatry
  4. Meta-analysisEfficacy and Safety of Polyunsaturated Fatty Acids Supplementation in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents: A Systematic Review and Meta-Analysis of Clinical TrialsHändel Mina Nicole, Rohde Jeanett Friis, Rimestad Marie Louise, Bandak Elisabeth, Birkefoss Kirsten, Tendal Britta, Lemcke Sanne, Callesen Henriette Edemann (2021). Nutrients
  5. Meta-analysisBaseline omega-3 nutritional status and supplementation response in pediatric attention-deficit/hyperactivity disorder: a systematic review and biomarker-stratified meta-analysisFu Xiao, Feng Ling, Jiang Mingyan, Li Jinrong (2026). Frontiers in Public Health